Novo Nordisk Expands R&D Facility in China - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novo Nordisk Expands R&D Facility in China



Novo Nordisk has invested $100 million in expanding its research centre in Beijing, China, to 12000 m2.

The extra space will accommodate future growth in protein technology, biology and pharmacology research activities, fulfilling the company’s key strategic objective to develop the full range of protein research capabilities in China. The expansion will also encourage stronger contributions from the science team in China, which currently consists of 130 scientists and is expected to increase to 200 at the new site.

The Beijing site has already contributed significantly to Novo Nordisk’s R&D portfolio in various biopharmaceutical disease areas, including diabetes.

“We see the investment in this new R&D facility as a win-win opportunity for both Novo Nordisk and China. Novo Nordisk recognises the strong science being performed in China and we want to bring innovation from Chinese scientists into our company to help tackle the growing burden of diabetes and other chronic diseases throughout the world,” Mads Krogsgaard Thomsen, chief science officer and executive vice president of Novo Nordisk said in a press statement.

The R&D centre, located in Beijing’s Zhongguancun Life Science Park, was first established in 2002. According to the company, it has since developed into a centre of excellence for molecular biology, protein chemistry and cell biology. The statement also adds that Novo Nordisk was the first international biopharmaceutical company to develop R&D operations in China in 1997.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here